The Deferasirox–AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Host iron availability is fundamental to mucormycosis pathogenesis. The combination of liposomal amphotericin B (LAmB) and deferasirox iron chelation therapy synergistically improved survival in diabetic mice with mucormycosis. To determine the safety of combination deferasirox plus LAmB therapy for mucormycosis, a multicentred, placebo-controlled, double-blinded clinical trial was conducted. METHODS: Twenty patients with proven or probable mucormycosis were randomized to receive treatment with LAmB plus deferasirox (20 mg/kg/day for 14 days) or LAmB plus placebo (NCT00419770, clinicaltrials.gov). The primary analyses were for safety and exploratory efficacy. RESULTS: Patients in the deferasirox arm (n=11) were more likely than those in the placebo arm (n=9) to have active malignancy, neutropenia and corticosteroid therapy, and were less likely to receive concurrent non-study antifungal therapy. Reported adverse events and serious adverse events were similar between the groups. However, death was more frequent in the deferasirox than in the placebo arm at 30 days (45% versus 11%, P=0.1) and 90 days (82% versus 22%, P=0.01). Global success (alive, clinically stable, radiographically improved) for the deferasirox arm versus the placebo arm at 30 and 90 days, respectively, was 18% (2/11) versus 67% (6/9) (P=0.06) and 18% (2/11) versus 56% (5/9) (P=0.2). CONCLUSIONS: Patients with mucormycosis treated with deferasirox had a higher mortality rate at 90 days. Population imbalances in this small Phase II study make generalizable conclusions difficult. Nevertheless, these data do not support a role for initial, adjunctive deferasirox therapy for mucormycosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, in a prospective RCT, the addition of DFX to patients with proven or probable mucormycosis treated with antifungal liposomal amphotericin B increased the mortality (Spellberg et al., 2011).”
From Iron in infection and immunity (2020) · cites this paper as Spellberg et al., 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, a recent clinical trial in patients after allogenic bone marrow transplantation who received the iron chelator desferrasirox in an attempt to improve the control of mucormycosis, a devastating invasive fungal infection in severely immuno-compromised patients, failed to show a clinical benefit (Spellberg et al., 2012).”
From Iron at the interface of immunity and infection (2014) · cites this paper as Spellberg et al., 2012
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The sample size was small in this RCT and confounders may have been present, leaving open questions but DFX may lack beneficial effects in mucormycosis.”
From Iron in infection and immunity (2020) · cites this paper as Spellberg et al., 2011
The cited source says what the claim attributes to it.
In the citing paper
“The sample size was small in this RCT and confounders may have been present, leaving open questions but DFX may lack beneficial effects in mucormycosis.”
From Iron in infection and immunity (2020) · cites this paper as Spellberg et al., 2011
In the citing paper
“However, a small, multicenter clinical study using desferasirox as an adjunct treatment in patients that develop mucormycosis after allogeneic bone marrow transplantation resulted in a rather unfavorable outcome, for reasons that are not clear [28].”
From The Iron age of host–microbe interactions (2015) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
Roden, M. M., Zaoutis, T. E., Buchanan, W. L., Knudsen, T. A., Sarkisova, T. A., Schaufele, R. L., Sein, M., Sein, T., Chiou, C. C., Chu, J. H., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/432579 · Cited by 3,044
Self-citationAscioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
Chamilos, G., Lewis, R. E., & Kontoyiannis, D. P. (2008) · Clinical Infectious Diseases · doi:10.1086/590004 · Cited by 826
Self-citationRecent Advances in the Management of Mucormycosis: From Bench to Bedside
Spellberg, B., Walsh, T. J., Kontoyiannis, D. P., Edwards, Jr., & Ibrahim, A. S. (2009) · Clinical Infectious Diseases · doi:10.1086/599105 · Cited by 548
Self-citationIncreasing Incidence of Zygomycosis (Mucormycosis), France, 1997–2006
Bitar, D., Van Cauteren, D., Lanternier, F., Dannaoui, E., Che, D., Dromer, F., Desenclos, J.-C., & Lortholary, O. (2009) · Emerging Infectious Diseases · doi:10.3201/eid1509.090334 · Cited by 429
Artis, W. M., Fountain, J. A., Delcher, H. K., & Jones, H. E. (1982) · Diabetes · doi:10.2337/diabetes.31.12.1109 · Cited by 369
Boelaert, J. R., de Locht, M., Van Cutsem, J., Kerrels, V, Cantinieaux, B., Verdonck, A., Van Landuyt, H. W., & Schneider, Y. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116419 · Cited by 340
Nisbet-Brown, E., Olivieri, N. F., Giardina, P. J., Grady, R. W., Neufeld, E. J., Séchaud, R., Krebs-Brown, A. J., Anderson, J. R., Alberti, D., Sizer, K. C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13309-0 · Cited by 328
The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice
Liu, M., Spellberg, B., Phan, Q. T., Fu, Y., Fu, Y., Lee, A. S., Edwards, J. E., Filler, S. G., & Ibrahim, A. S. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42164 · Cited by 324
Self-citationThe iron chelator deferasirox protects mice from mucormycosis through iron starvation
Ibrahim, A. S., Gebermariam, T., Fu, Y., Lin, Husseiny, M. I., French, S. W., Schwartz, J., Skory, C. D., Edwards, J. E., & Spellberg, B. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32338 · Cited by 308
Self-citation
Cited by
Items 101–200 of 311
COVID-19 and oral implications: An updated review
Boyapati, R., Dhulipalla, R., Kolaparthy, L., & Bodduru, R. (2021) · Journal of Oral and Maxillofacial Pathology · doi:10.4103/jomfp.jomfp_198_21 · Cited by 38
“These fungi affect the immunocompromised patients those that are on high‐dose glucocorticoids, hemodialysis and uncontrolled diabetes mellitus.[26] In a healthy individual, the spores and hyphae are attacked by immune cells and destroyed by monocytes, macrophages and polymorphonuclear phagocytes.”
BackgroundIron starvation induces apoptosis in rhizopus oryzae in vitro
Shirazi, F., Kontoyiannis, D. P., & Ibrahim, A. S. (2015) · Virulence · doi:10.1080/21505594.2015.1009732 · Cited by 38
“01) compared to those treated with LAmB alone.(16) It is imperative to point that this study suffered from shortcomings including patients in the deferasirox arm were more likely than placebo patients to have active malignancy, neutropenia, corticosteroid therapy, and less likely to have received additional antifungal…”
BackgroundResultSelf-citationRuhnke, M., & Schwartz, S. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716656381 · Cited by 37
Sahu, R. K., Salem-Bekhit, M. M., Bhattacharjee, B., Almoshari, Y., Ikbal, A. M. A., Alshamrani, M., Bharali, A., Salawi, A., Widyowati, R., Alshammari, A., et al. (2021) · Antibiotics · doi:10.3390/antibiotics10091079 · Cited by 38
“Deferasirox also countered iron’s inhibitory effect on neutrophil chemotaxis [64].”
BackgroundMadhavan, Y., Sai, K. V., Shanmugam, D. K., Aashabharathi, M., Devi, G. K., Mohanta, Y. K., Venugopal, D. C., Mohanta, T. K., Sharma, N., & Saravanan, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133620 · Cited by 37
“It may be administered intravenously in the form of a delayed-release tablet or even as a syrup [65,78].”
BackgroundInvestigation of the Biological Properties of (Hetero)Aromatic Thiosemicarbazones
Serda, M., Mrozek‐Wilczkiewicz, A., Jampílek, J., Peško, M., Kráľová, K., Vejsová, M., Musioł, R., Ratuszna, A., & Polański, J. (2012) · Molecules · doi:10.3390/molecules171113483 · Cited by 40
“DFO was tested as an ancillary drug with amphotericin B in antifungal therapy in a clinical trial [20,21].”
BackgroundIron acquisition strategies in pathogenic fungi
Takemura, K., Kolasinski, V., Poeta, M. D., de Sa, N. F. V., Garg, A., Ojima, I., Poeta, M. D., & de Sá, N. P. (2025) · mBio · doi:10.1128/mbio.01211-25 · Cited by 40
“2B), which are not utilized by the fungus, have shown protective effects in mice with diabetic ketoacidosis and have been employed in clinical trials (126–128).”
Symeonidis, A. S., & Marangos, M. N. (2012) · InTech eBooks · doi:10.5772/34760 · Cited by 54
Connecting iron regulation and mitochondrial function in Cryptococcus neoformans
Horianopoulos, L. C., & Kronstad, J. W. (2019) · Current Opinion in Microbiology · doi:10.1016/j.mib.2019.04.002 · Cited by 32
Beyond Conventional Antifungals: Combating Resistance Through Novel Therapeutic Pathways
Hetta, H. F., Melhem, T., Aljohani, H. M., Salama, A., Ahmed, R., Elfadil, H., Alanazi, F. E., Ramadan, Y. N., Battah, B., Rottura, M., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18030364 · Cited by 35
“LAmB showed promising effects against several fungal infections such as mucormycosis [280–282], aspergillosis [283–285], candidiasis [286–288], Candida menin-goencephalitis [289], cryptococcosis [88,290], histoplasmosis [291], and other uncommon but highly invasive mycoses, such as fusariosis [292].”
COVID-19-Associated Mucormycosis: A Matter of Concern Amid the SARS-CoV-2 Pandemic
Chandley, P., Subba, P., & Rohatgi, S. (2022) · Vaccines · doi:10.3390/vaccines10081266 · Cited by 35
“It was reported that Deferasirox increased the mortality rates in mucormycosis patients [171,172].”
BackgroundCombination therapy in Mucormycosis: Current evidence from the world literature, a mini review
Meena, D. S., Kumar, D., & Bohra, G. K. (2022) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2022.101332 · Cited by 32
“DEFEAT Mucor study (randomized trial) showed increased 90 days mortality with a deferasirox/ L-AMB combination [45].”
BackgroundMucormycosis: A Rare Fungal Infection in Tornado Victims
Austin, C. L., Finley, P. J., Mikkelson, D., & Tibbs, B. M. (2013) · Journal of Burn Care & Research · doi:10.1097/bcr.0b013e318299d4bb · Cited by 33
Mucormicosis: perspectiva de manejo actual y de futuro
Martín-Gómez, M. T., & Salavert, M. (2021) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2021.04.003 · Cited by 37
Sheldon, J. R., Himmel, L. E., Kunkle, D. E., Monteith, A. J., Maloney, K. N., & Skaar, E. P. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010809 · Cited by 29
Fungal Infections Complicating Lung Transplantation
Clark, N. M., WEIGT, S. S., Fishbein, M. C., Kubak, B., Belperio, J. A., & Lynch, J. P. (2018) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0037-1617443 · Cited by 33
Therapeutic Opportunities for Hepcidin in Acute Care Medicine
Chawla, L. S., Beers-Mulroy, B., & Tidmarsh, G. F. (2019) · Critical Care Clinics · doi:10.1016/j.ccc.2018.11.014 · Cited by 28
Multani, A., Reveron‐Thornton, R. F., Garvert, D. W., Gómez, C. A., Montoya, J. G., & Lui, N. S. (2019) · Mycoses · doi:10.1111/myc.12954 · Cited by 28
COVID-19-Associated Pulmonary Mucormycosis
Krishna, V., Bansal, N., Morjaria, J. B., & Kaul, S. (2022) · Journal of Fungi · doi:10.3390/jof8070711 · Cited by 27
“Combination with desferasirox and amphotericin B have failed to show benefit in a double-blind randomized control trial [47].”
BackgroundInvasive rhino-orbito-cerebral mucormycosis in a diabetic patient – the need for prompt treatment
Chow, V. J., Khan, S., Balogun, A., Mitchell, D., & Mühlschlegel, F. A. (2014) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2014.12.002 · Cited by 27
Dadwal, S., Tegtmeier, B., Liu, X., Frankel, P. H., Ito, J. I., Forman, S. J., & Pullarkat, V. A. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12421 · Cited by 27
“Median age [range] 49 [18, 71] 49 [18, 68] 47 [18, 71]”
Mucormycosis: what emergency physicians need to know?
Long, B., & Koyfman, A. (2015) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2015.08.037 · Cited by 27
“Unlike deferoxamine, this agent has support for adjunctive therapy inmurinemodels, but human trials are not supportive currently [31].”
BackgroundLeal, S. M., Roy, S., Vareechon, C., Carrion, S. D. J., Clark, H., López‐Berges, M. S., Pietro, A. D., Schrettl, M., Beckmann, N., Redl, B., et al. (2013) · PLoS Pathogens · doi:10.1371/annotation/4f388450-90fe-4c65-9b9b-71a2b7935ac0 · Cited by 27
Fungal Infections of the Brain
González-Lara, M. F., & Ostrosky-Zeichner, L. L. (2020) · Current clinical neurology · doi:10.1007/978-3-030-56084-3_10 · Cited by 28
Muthu, V., Ratnakara, R. G., Agarwal, R., Prasad, K. T., Sehgal, I. S., Dhooria, S., Aggarwal, A. N., Rudramurthy, S. M., Singh, H., Garg, M. K., et al. (2023) · Mycoses · doi:10.1111/myc.13591 · Cited by 26
Czech, M. M., & Cuellar‐Rodríguez, J. (2024) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2024.11.008 · Cited by 26
Invasive Mold Infections in Solid Organ Transplant Recipients
Crabol, Y., & Lortholary, O. (2014) · Scientifica · doi:10.1155/2014/821969 · Cited by 26
“Population imbalances in this small studymake generalizable conclusions difficult [120].”
BackgroundCandoni, A., Aversa, F., Busca, A., Cesaro, S., Girmenia, C., Luppi, M., Rossi, G., Venditti, A., Nosari, A., & Pagano, L. (2014) · Journal of Chemotherapy · doi:10.1179/1973947814y.0000000224 · Cited by 24
Enfermedad fúngica invasora por Scedosporium, Fusarium y Mucor
Pemán, J., & Salavert, M. (2014) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2014.05.002 · Cited by 39
Chakrabarti, A., & Singh, S. (2020) · Current Fungal Infection Reports · doi:10.1007/s12281-020-00406-2 · Cited by 24
Mucormycosis: The hidden and forgotten disease
Darwish, R. M., Almasri, M., & Almasri, M. (2022) · Journal of Applied Microbiology · doi:10.1111/jam.15487 · Cited by 25
“Other iron chelating drugs, such as deferasirox and deferiprone, do not act as siderophores and hence do not raise the risk of mucormycosis (Ibrahim et al., 2008; Spellberg et al., 2012).”
BackgroundMucormycosis following burn injuries: A systematic review
Dang, J., Goel, P., Choi, K. J., Massenzio, E. M., Landau, M. J., Pham, C. H., Huang, S., Yenikomshian, H. A., Spellberg, B. J., & Gillenwater, J. T. (2022) · Burns · doi:10.1016/j.burns.2022.05.012 · Cited by 25
Self-citationStanford, F. A., Matthies, N., Cseresnyés, Z., Figge, M. T., Hassan, M. I. A., & Voigt, K. (2021) · Journal of Fungi · doi:10.3390/jof7040272 · Cited by 23
“Interestingly, preclinical data conducted on DKA murine models of Rhizopus arrhizus infection found that deferasirox treatment was as effective as liposomal amphotericin B (LAMB) therapy, while combination therapy of deferasirox-LAMB acted synergistically to improve survival [44,46,47].”
BackgroundPetzer, V., Wermke, M., Tymoszuk, P., Wolf, D., Seifert, M., Ovaçin, R., Berger, S., Orth-Höller, D., Loacker, L., Weiss, G., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000043 · Cited by 22
“Notably, application of deferasirox for mucormycosis in mice and humans yielded inconsistent outcomes, so that further work up is warranted and data must be interpreted with caution.(22) Moreover, pharmacologic increase of hepcidin levels, being the master regulator of systemic iron homeostasis, may also turn out to b…”
BackgroundRecent advances in the treatment of life-threatening, invasive fungal infections
Drew, R. H., Townsend, M. L., Pound, M. W., Johnson, S. W., & Perfect, J. R. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.838217 · Cited by 32
“In addition, increased iron serum concentrations have been associated with the development of IA and mucormycosis among certain patients [13].”
BackgroundResultSelf-citationFocus on invasive mucormycosis in paediatric haematology oncology patients: a series of 11 cases
Phulpin-Weibel, A., Rivier, A., Leblanc, T. M., Bertrand, Y., & Chastagner, P. B. (2012) · Mycoses · doi:10.1111/myc.12010 · Cited by 26
Deferasirox in mucormycosis: hopefully, not defeated
Soman, R., Gupta, N., Shetty, A., & Rodrigues, C. S. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr529 · Cited by 22
Gu, Y., Singh, S., Alqarihi, A., Alkhazraji, S., Gebremariam, T., Youssef, E. G., Liu, H., Fan, X., Jiang, W.-R., Andes, D. R., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.ads7369 · Cited by 22
Self-citationMetal Ions and Infectious Diseases. An Overview from the Clinic
Carver, P. L. (2013) · Metal ions in life sciences · doi:10.1007/978-94-007-7500-8_1 · Cited by 22
Faiyazuddin, M., Sophia, A., Ashique, S., Gholap, A. D., Gowri, S., Mohanto, S., Karthikeyan, C., Nag, S., Hussain, A., Akhtar, M. S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1264502 · Cited by 22
New Insights on Mucormycosis and Its Association With the COVID-19 Pandemic
Alshahawey, M., El-Housseiny, G. S., Elsayed, N. S., Alshahrani, M. Y., Wakeel, L. M. E., & Aboshanab, K. M. (2021) · Future Science OA · doi:10.2144/fsoa-2021-0122 · Cited by 21
Mucormycosis threats: A systemic review
Prakash, S., & Kumar, A. (2022) · Journal of Basic Microbiology · doi:10.1002/jobm.202200334 · Cited by 21
“In contrast, deferasirox administered in combination with AMB showed a detrimental effect on the HM patients [58].”
BackgroundAn old confusion: Entomophthoromycosis versus mucormycosis and their main differences
Acosta-España, J. D., & Voigt, K. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1035100 · Cited by 22
“Moreover, the application of the xenosiderophore deferasirox resulted in an increased lethality in mice (Spellberg et al., 2012).”
BackgroundDeferasirox as adjunctive therapy for mucormycosis
Donnelly, J. P., & Lahav, M. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr540 · Cited by 20
Mucormycosis pathogenesis: Beyond Rhizopus
Spellberg, B. J. (2017) · Virulence · doi:10.1080/21505594.2017.1364335 · Cited by 25
Self-citationHierro e infección fúngica invasiva
Álvarez, F., Fernández‐Ruiz, M., & Aguado, J. M. (2013) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2013.04.002 · Cited by 25
The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis)
Lortholary, O., Fernández‐Ruiz, M., & Perfect, J. R. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw394 · Cited by 19
Self-citationPseudomonas Synergizes with Fluconazole against Candida during Treatment of Polymicrobial Infection
Hattab, S., Dagher, A.-M., & Wheeler, R. T. (2022) · Infection and Immunity · doi:10.1128/iai.00626-21 · Cited by 22
Khasawneh, F. A., Dai, Y., Walker, J., & Halloush, R. A. (2013) · International Journal of General Medicine · doi:10.2147/ijgm.s52718 · Cited by 20
Iron chelation therapy as a treatment for Pythium insidiosum in an animal model
Zanette, R. A., Alves, S. H., Pilotto, M. B., Weiblen, C., Fighera, R. A., Wolkmer, P., Flores, M. M., & Santúrio, J. M. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks534 · Cited by 20
Novel Approaches in the Management of Mucormycosis
Lamoth, F. (2023) · Current Fungal Infection Reports · doi:10.1007/s12281-023-00463-3 · Cited by 20
Emerging Invasive Fungal Diseases in Transplantation
Parize, P., Rammaert, B., & Lortholary, O. (2012) · Current Infectious Disease Reports · doi:10.1007/s11908-012-0296-y · Cited by 19
Mucormycosis: a new concern in the transplant ward?
Robin, C., Alanio, A., & Cordonnier, C. (2014) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000082 · Cited by 19
“Because of the role of iron overload in the occurrence of mucormycosis, and of the animal data showing the benefit of combining L-AmB and deferasirox [77], a randomized, double-blinded trial, the Deferasirox–AmBisome Therapy for Mucormycosis study, compared the combination of L-AmB with either deferasirox or placebo i…”
Adams, R., & Bird, R. J. (2013) · Therapeutic Advances in Hematology · doi:10.1177/2040620712472355 · Cited by 19
“Although there are some data that deferasirox may have potential as an adjunct therapy in patients with mucormycosis [Ibrahim et al. 2007], a recent prospective trial failed to show benefit for deferasirox in combination with standard treatment as upfront therapy [Spellberg et al. 2012].”
ResultHaidar, G., & Singh, N. (2018) · Transplantation · doi:10.1097/tp.0000000000002353 · Cited by 18
El tratamiento de la mucormicosis (cigomicosis) en el siglo xxi
Ruíz-Camps, I., & Salavert, M. (2018) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2018.09.001 · Cited by 20
Hepatic mucormycosis with abscess formation
Su, H. K., Thompson, G. R., & Cohen, S. H. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.02.021 · Cited by 18
“Chelation therapy was considered in our patient; however, limited data regarding the efficacy of these agents exist—and a recently completed randomized, double-blind, placebo-controlled trial demonstrated a higher mortality in patients treated with deferasirox (Spellberg et al., 2012).”
BackgroundEmergence of the Molds Other than Aspergillus in Immunocompromised Patients
Arif, S., & Perfect, J. R. (2017) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2017.04.014 · Cited by 18
Self-citationChitasombat, M. N., & Niparuck, P. (2018) · Infectious Disease Reports · doi:10.4081/idr.2018.7765 · Cited by 17
“Alanine aminotransferase (U/L) 32 (19-122) 35 (11-48) 39 (37-82)”
Isavuconazole: an azole active against mucormycosis
Roilides, E., & Antachopoulos, C. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00127-4 · Cited by 18
Combination Antifungal Therapy: When, Where, and Why
Belanger, E. S., Yang, E., & Forrest, G. N. (2015) · Current Clinical Microbiology Reports · doi:10.1007/s40588-015-0017-z · Cited by 18
How metals fuel fungal virulence, yet promote anti-fungal immunity
Alselami, A., & Drummond, R. A. (2023) · Disease Models & Mechanisms · doi:10.1242/dmm.050393 · Cited by 18
Drugs Active against Fungi, Pneumocystis, and Microsporidia
Rex, J. H., & Stevens, D. A. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00039-4 · Cited by 19
Opportunistic and Systemic Fungi
Kosmidis, C., & Denning, D. W. (2016) · Elsevier eBooks · doi:10.1016/b978-0-7020-6285-8.00189-1 · Cited by 20
Schwarz, P., Nikolskiy, I., Bidaud, A.-L., Sommer, F. O., Bange, G., & Dannaoui, É. (2022) · Journal of Fungi · doi:10.3390/jof8020115 · Cited by 17
“A combination of two antifungal drugs, voriconazole and anidulafungin, showed only indifference for the treatment of aspergillosis [23], while the combination of an antifungal with an iron chelator, liposomal amphotericin B and deferasirox even exhibited antagonism for the treatment of mucormycosis [24].”
BackgroundLafont, E., Aguilar, C., Vironneau, P., Kania, R. E., Alanio, A., Poirée, S., Lortholary, O., & Lanternier, F. (2017) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2016.09.004 · Cited by 20
Carvalhaes, C. G., Rhomberg, P. R., Huband, M. D., Pfaller, M. A., & Castanheira, M. (2023) · Journal of Fungi · doi:10.3390/jof9020241 · Cited by 16
Almyroudis, N. G., & Segal, B. H. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.10.141 · Cited by 16
Gastrointestinal Mucormycosis of the Jejunum in an Immunocompetent Patient: A Case Report
Sun, M., Hou, X., Wang, X., Chen, G., & Zhao, Y.-P. (2017) · Medicine · doi:10.1097/md.0000000000006360 · Cited by 15
“However, in some clinical studies, the combination of deferasirox and amp B did not produce a better prognosis.([24]) Whether deferasirox can improve the prognosis or be used as an alternative treatment option still requires confirmation with more reliable clinical studies.”
ResultNon-Aspergillusmould lung infections
Puerta‐Alcalde, P., & García‐Vidal, C. (2022) · European Respiratory Review · doi:10.1183/16000617.0104-2022 · Cited by 14
Andreani, G., Fadda, G. L., Gned, D., Dragani, M., Cavallo, G. P., Monticone, V., Morotti, A., Gobbi, M. D., Guerrasio, A., D’Avolio, A., et al. (2019) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2019.061 · Cited by 15
Rhino-orbital Cerebral Mucormycosis
Ak, A. K., & Gupta, V. (2021) · StatPearls · Cited by 13
Risum, M., Helweg‐Larsen, J., Petersen, S. L., Kampmann, P., Overgaard, U. M., Fassi, D. E., Nielsen, O. J., Brabrand, M., Rubek, N., Munksgaard, L., et al. (2020) · Journal of Fungi · doi:10.3390/jof6040268 · Cited by 13
“Other prospective studies, not restricted to haematological patients, have included 18 to 32 proven cases [21,33,34] and retrospective haematological studies of 20 to 74 proven cases during up to 20 year study periods [8,9,35,36].”
BackgroundResultRole of Iron Chelators in Mucormycosis
Medhi, B., Mahalmani, V., Sarma, P., & Prakash, A. (2021) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_604_21 · Cited by 13
“[23] Patients with DKA have greater chance of acquiring rhinocerebral ketoacidosis because of release of iron from binding proteins.”
Miltefosine: A Repurposing Drug against Mucorales Pathogens
Xisto, M. I. D. D. S., Rollin‐Pinheiro, R., Rochetti, V. P., de Castro-Almeida, Y., Borba-Santos, L. P., dos Santos, G. M. P., Cypriano, J. B. S., Abreu, F. D. Á., Rozental, S., & Barreto‐Bergter, E. (2023) · Journal of Fungi · doi:10.3390/jof9121166 · Cited by 12
Tumor shape pulmonary mucormycosis associated with sinonasal aspergillosis in a diabetic patient
Point, S., Gabriel, F., Bégueret, H., Jougon, J. B., Lanternier, F., Grenouillet, F., Fattah, M. A., Catherinot, É., Rahérison, C., & Blanchard, É. (2017) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2017.08.001 · Cited by 12
“Unfortunately, deferasirox, an iron chelator was associated with a higher mortality rate at 90 days in clinical trials [20,21].”
Walsh, T. J., Lewis, R. E., & Adler‐Moore, J. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz091 · Cited by 13
“mucormycosis [41, 42], and other less common, deeply invasive”
BackgroundLi, J., Nguyen, C. T., & Garcia‐Diaz, J. (2015) · Journal of Fungi · doi:10.3390/jof1030345 · Cited by 16
Schneidawind, D., Nann, D., Vogel, W., Faul, C., Fend, F., Horger, M., Kanz, L., & Bethge, W. A. (2012) · Transplant Infectious Disease · doi:10.1111/tid.12019 · Cited by 12
Angioinvasive mucormycosis and paradoxical stroke: a case report
Mititelu, R., Bourassa‐Blanchette, S., Sharma, K., & Roth, V. R. (2016) · JMM Case Reports · doi:10.1099/jmmcr.0.005048 · Cited by 12
“Conclusion: Although deferiprone, a newer iron chelator agent, has antifungal properties in vivo, this case illustrates that angioinvasive Rhizopus infections can occur in patients treated with deferiprone.”
BackgroundResultInfluentialExtrapolating Antifungal Animal Data to Humans—Is It Reliable?
Stevens, V. M., Mueller, S. W., Reynolds, P., MacLaren, R., & Kiser, T. H. (2020) · Current Fungal Infection Reports · doi:10.1007/s12281-020-00370-x · Cited by 12
Part 2: mucormycosis: focus on therapy
Lynch, J. P., & Zhanel, G. G. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2224564 · Cited by 12
“The first RCT (DEFEAT Mucor study) included only 20 patients with MCR [118].”
BackgroundFocusing COVID-19-associated mucormycosis: a major threat to immunocompromised COVID-19
Sharma, N., Wani, S. N., Behl, T., Singh, S., Zahoor, I., Sehgal, A., Bhatia, S., Al‐Harrasi, A., Aleya, L., & BUNGAU, S. G. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-24032-2 · Cited by 12
Rhino-orbito-cerebral mucormycosis and its resurgence during COVID-19 pandemic: A review
Karkhur, S., Soni, D., Chauhan, K., Sarkar, D., Gautam, M., Verma, S., Nyodu, R., Yadav, N. S., & Sharma, B. B. (2022) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1219_22 · Cited by 13
“However, outcomes of the Deferasirox‐AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study does not recommend deferasirox as part of an initial combination regimen for the treatment of mucormycosis.[56]”
BackgroundDuration of systemic antifungal therapy for patients with invasive fungal diseases: A reassessment
Gressens, S. B., Rouzaud, C., Lamoth, F., Calandra, T., Lanternier, F., & Lortholary, O. (2025) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2025.101347 · Cited by 10
Diagnosis and Treatment of Mucormycosis in Patients with Hematological Malignancies
Asano‐Mori, Y. (2016) · Medical Mycology Journal · doi:10.3314/mmj.16.006 · Cited by 10
Mucormycoses: Actualités thérapeutiques
Pilmis, B., Lanternier, F., & Lortholary, O. (2013) · médecine/sciences · doi:10.1051/medsci/201329s106 · Cited by 9
“Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The Deferasirox-AmBisome therapy for mucormycosis (DEFEAT Mucor) study : a randomized, doubleblinded, placebo-controlled trial.”
InfluentialIzaguirre-Anariba, D., Chee, F., Thet, Z., & Lanza, J. (2018) · Case Reports in Infectious Diseases · doi:10.1155/2018/6283701 · Cited by 9
Treatment of Non-Aspergillus Mold Infections: a Focus on Mucormycosis and Fusariosis
Phoompoung, P., & Luong, M. (2019) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-019-00205-5 · Cited by 8
Spellberg, B. J., & Maertens, J. A. (2019) · Springer eBooks · doi:10.1007/978-1-4939-9034-4_34 · Cited by 10
Self-citationPrevalence of COVID-19 Associated Mucormycosis in a German Tertiary Care Hospital
Scharmann, U., Herbstreit, F., Steckel, N. K., Dedy, J., Buer, J., Rath, P., & Verhasselt, H. L. (2022) · Journal of Fungi · doi:10.3390/jof8030307 · Cited by 9
“Furthermore, half of cultures are false negative [11,12].”
BackgroundAn unusual ulcer: A case of cutaneous mucormycosis caused by Rhizopus oryzae
Gardiner, B. J., Simpson, I. J., Khuu, M. H., Kidd, S. E., Lo, C. H., & Jenkin, G. (2014) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2014.11.003 · Cited by 8
Cortez, J., Gomes, B. C., Speidel, A., Peixoto, C., Selicka, E., Valente, C., Figueiredo, P., & Vieira, A. (2013) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2013.02.008 · Cited by 8
“The Deferasirox-AmBisome Therapy for mucormycosis (DEFEAT Mucor) study was the first randomized clinical trial conducted on patients with mucormycosis, and demonstrated that adjunctive deferasirox therapy did not improve outcomes of the disease [28].”
BackgroundFungal Necrotizing Skin and Soft Tissue Infections
Bartram, L., & Aaron, J. G. (2019) · Current Fungal Infection Reports · doi:10.1007/s12281-019-00355-5 · Cited by 8
Commentary: “Fungal Infections of Oral Cavity: Diagnosis, Management, and Association with COVID-19”
Bharatha, A., Kandamaran, L., & Krishnamurthy, K. (2021) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-021-01017-9 · Cited by 8
Uppuluri, P., Alqarihi, A., & Ibrahim, A. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.21013-3 · Cited by 9
Self-citationItoh, K., Tsutani, H., Mitsuke, Y., & Iwasaki, H. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1210747 · Cited by 7
“, 2019), unexpectedly, a higher mortality rate at 90 days was seen with the combination than with L-AMB alone in a randomized controlled trial (Spellberg et al., 2012).”
BackgroundResultDrug Interactions of Antifungal Agents: Clinical Relevance and Implications
Corrêa-Junior, D., Frasés, S., & Araújo, G. R. D. S. (2025) · Current Tropical Medicine Reports · doi:10.1007/s40475-024-00336-w · Cited by 7
“Similarly, pairing AmB with PCZ is recommended for difficult cases, with PCZ providing additional benefits for resistant mucormy-cosis [76–78].”
Asano‐Mori, Y. (2017) · Medical Mycology Journal · doi:10.3314/mmj.17.013 · Cited by 8
桂一, 三., 信樹, 青., Aoki, Y., 修一, 阿., 敏, 岩., 一信, 尾., 笠原, 敬., 淳一, 門., 岸田直樹, 治, 小., et al. (2014) · Kansenshogaku zasshi · doi:10.11150/kansenshogakuzasshi.88.1 · Cited by 7
Metadata
- Authors
- Spellberg, B., Ibrahim, A. S., Chin-Hong, P. V., Kontoyiannis, D. P., Morris, M. I., Perfect, J. R., Fredricks, D., & Brass, E. P.
- Affiliations
- University of California, Los Angeles (US)
- University of California, San Francisco (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Miami (US)
- Duke Medical Center (US)
- University of Washington (US)
- Corresponding author
- Spellberg, Brad
- ORCID
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-09-20
- Volume
- 67
- Issue
- 3
- Pages
- 715-722
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- PMC
- PMC3383100
- OpenAlex
- W2116858171
- Cited by
- 308
- References
- 32
- Citations by year
- 2026: 13 · 2025: 15 · 2024: 9 · 2023: 22 · 2022: 24 · 2021: 30 · 2020: 16 · 2019: 20 · 2018: 22 · 2017: 16 · 2016: 22 · 2015: 17 · 2014: 33 · 2013: 25 · 2012: 19
- FWCI
- 17.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Antimicrobial Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Gilead Sciences
- Astellas Pharma
- National Institutes of Health (UL1TR000124)
- National Institute of Allergy and Infectious Diseases (R01AI081719, R01AI063503)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Mycology
- Keywords
- mucormycosis, deferasirox, liposomal amphotericin B, iron chelation, adjunctive therapy, mortality, treatment safety
- MeSH terms
- Deferasirox, Adult, Aged, Amphotericin B, Animals, Antifungal Agents, Benzoates, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Iron Chelating Agents, Male, Middle Aged, Mucormycosis, Placebos, Triazoles, Survival Analysis, Treatment Outcome, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.